Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stake Raised by Jane Street Group LLC

Jane Street Group LLC grew its position in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 34.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,884 shares of the company’s stock after purchasing an additional 4,365 shares during the period. Jane Street Group LLC’s holdings in Biohaven Pharmaceutical were worth $667,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of BHVN. Wells Fargo & Company MN boosted its stake in shares of Biohaven Pharmaceutical by 38.2% in the 1st quarter. Wells Fargo & Company MN now owns 41,184 shares of the company’s stock valued at $1,060,000 after purchasing an additional 11,373 shares in the last quarter. Swiss National Bank lifted its position in Biohaven Pharmaceutical by 104.6% during the 1st quarter. Swiss National Bank now owns 31,300 shares of the company’s stock worth $806,000 after buying an additional 16,000 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Biohaven Pharmaceutical by 118.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 87,642 shares of the company’s stock worth $2,258,000 after buying an additional 47,505 shares in the last quarter. American International Group Inc. lifted its position in Biohaven Pharmaceutical by 187.1% during the 1st quarter. American International Group Inc. now owns 20,303 shares of the company’s stock worth $523,000 after buying an additional 13,231 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Biohaven Pharmaceutical by 158.5% during the 1st quarter. Northern Trust Corp now owns 303,830 shares of the company’s stock worth $7,827,000 after buying an additional 186,274 shares in the last quarter. Institutional investors own 80.85% of the company’s stock.

Shares of NYSE BHVN opened at $35.00 on Thursday. Biohaven Pharmaceutical Holding Co Ltd has a 12-month low of $16.50 and a 12-month high of $44.28. The stock has a market cap of $1.51 billion, a P/E ratio of -7.12 and a beta of 1.47.

Biohaven Pharmaceutical (NYSE:BHVN) last released its earnings results on Tuesday, August 14th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.68) by $0.67. Analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -5.41 earnings per share for the current year.

Several brokerages recently issued reports on BHVN. ValuEngine upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday, October 3rd. Cantor Fitzgerald reiterated a “buy” rating and set a $57.00 price target on shares of Biohaven Pharmaceutical in a research report on Monday, October 1st. Piper Jaffray Companies set a $65.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Morgan Stanley upped their price target on shares of Biohaven Pharmaceutical from $44.00 to $45.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 11th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $43.00 price target on shares of Biohaven Pharmaceutical in a research report on Friday, August 17th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $47.29.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Read More: How to Invest in Growth Stocks

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply